On April 17, 2026 OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, reported that the AACR (Free AACR Whitepaper) 2026 abstract reporting interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab (durvalumab) and platinum-based chemotherapy in patients with resectable early stage non-small cell lung cancer (NSCLC) has been published.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Summary of the abstract: Perioperative PD-(L)1 inhibitors combined with chemotherapy are now standard for resectable early-stage NSCLC, but further improvements in pathological complete response (pCR) and survival are still needed. IPH5201, an anti-CD39 antibody, aims to enhance antitumor immunity by reducing immunosuppressive adenosine and increasing ATP levels. In the Phase 2 MATISSE study, IPH5201 was added to durvalumab and chemotherapy in patients with stage II–IIIA NSCLC. Among 40 patients, the treatment showed a favorable safety profile and achieved a pCR rate of 27.5% (all), rising to 35.7% in PD-L1 ≥1% and 50% in PD-L1 ≥50% patients, comparing favorably with the 17.2%, 21.2% and 27.5% reported for durvalumab + chemo in the AEGEAN study (Heymach, 2023). Biomarker analyses confirmed CD39 target engagement and suggested a link between CD39+ tumor cell density and response. These results compare favorably to prior standards and support the continuation of the study with the recruitment of PD-L1≥1% pts.

Presentation details:

Session CTPL04 – Advances in Immunotherapy
CT231 – Dual CD39 and PD-L1 inhibition: Interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab (durva) and platinum-based chemotherapy (CT) in patients (pts) with resectable NSCLC.

Session Date/Time: April 21, 2026, 10:45 AM – 11:00 AM Hall H – Ground Level – Convention Center

Presenter: Pr. Fabrice Barlesi, CEO of Institut Gustave Roussy

About IPH5201 antibody
IPH5201 is a humanized CD39 blocking antibody codeveloped by Innate Pharma and AstraZeneca (AZ).
OREGA Biotech entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody (IPH5201) has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody).

About NCT05742607 clinical trial
MATISSE is a Phase 2 multicenter single-arm study (NCT05742607) evaluating neoadjuvant and adjuvant treatment with IPH5201 in combination with durvalumab (anti-PD-L1, AZ) and chemotherapy in treatment-naïve patients with resectable early-stage non-small cell lung cancer (NSCLC). The primary objectives of the study are to assess antitumor activity of neoadjuvant treatment based on pathological complete response (pCR) and safety. More information on the Phase 2 clinical trial is accessible online.

(Press release, OREGA BIOTECH, APR 17, 2026, View Source [SID1234664546])

On April 17, 2026 Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, reported that it will be presenting a poster on its lead asset AT-108 at the AACR (Free AACR Whitepaper) Annual Meeting, held in San Diego, California, US, from 17-22 April 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AT-108 is a transformative gene therapy utilizing Asgard’s in vivo cell reprogramming technology to directly reprogram tumor cells into dendritic cells. This approach forces these tumor cells to present their tumor antigens, ultimately leading to a personalized anti-tumor immune response. Asgard is progressing its first-in-class therapy toward clinical development, with a focus on solid tumors, and is advancing IND-enabling studies and CMC development.

The poster presentation, titled ‘Preclinical efficacy and biomarker characterization of AT-108, a first-in-class in situ tumor-to-dendritic cell reprogramming agent’, will detail preclinical data demonstrating that AT-108 induces systemic, dose-dependent efficacy with broad tumor activity. Key biomarker parameters were highlighted to be explored in future clinical development.

Details of the poster presentation are as follow:

Poster title: Preclinical efficacy and biomarker characterization of AT-108, a first-in-class in situ tumor-to-dendritic cell reprogramming agent

Presenter: Fabio Rosa, Asgard Therapeutics

Authors: Fritiof Åkerström1, Xavier Catena1, Marta Santiago2, Ana Perego1, Ruixian Liu1, Arun Sundaramurthy1, Lihan Xie1, Emilie Renaud1, Andreea-Medeea Matei1, Xiaoli Huang1, Emma Leire1, Ozcan Met2, Inge-Marie Svane2, Shane Olwill1, Cristiana Pires1, Filipe Pereira3, Fabio Rosa1

Poster session: Session LBPO.ET04 – Late-Breaking Research: Experimental and Molecular Therapeutics 4

Session date and time: 22 April, 2026, 9:00 AM – 12:00 PM PDT

Location: Section 53

Poster number: LB455 / 2

1Asgard Therapeutics AB, Lund, Sweden,2National Center of Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark,3Molecular Medicine and Gene Therapy, Lund Stem Cell Centre, Lund University, Lund, Sweden

The abstract is available to view via the AACR (Free AACR Whitepaper) online planner.

(Press release, Asgard Therapeutics, APR 17, 2026, View Source [SID1234664467])

On April 17, 2026 Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel small molecule precision cancer therapies, reported preclinical data supporting its potentially best-in-class KIF18A inhibitor, ATX-295, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 taking place April 17-22 in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The strength and consistency of the preclinical results supporting our KIF18A program reinforce our confidence in ATX-295 as a novel therapeutic targeting a fundamental vulnerability in cancers with high levels of chromosomal instability," said Serena Silver, Ph.D., Chief Scientific Officer of Accent Therapeutics. "We are further advancing our commitment to maximize ATX-295’s potentially transformative impact for cancer patients by exploring AI-guided tools to assess chromosomal instability."

The company’s presentation includes preclinical data demonstrating the strong anti-tumor activity of ATX-295 across multiple solid tumor indications with high levels of chromosomal instability. The molecule showed potent in vitro activity in high-grade serous ovarian cancer (HGSOC), squamous non-small cell lung cancer (sqNSCLC), and triple-negative breast cancer (TNBC) cell lines, leading to cell cycle arrest and apoptosis. ATX-295 showed robust and durable tumor regression in patient-derived xenograft models of HGSOC, sqNSCLC and TNBC exhibiting whole-genome doubling (WGD), supporting WGD and chromosomal instability as predictive markers of tumor sensitivity to ATX-295. The results also include proof of concept for a novel, artificial intelligence (AI)-based method capable of rapidly detecting WGD in clinical samples, providing the foundation for a clinically feasible biomarker.

ATX-295 is currently under investigation in a first-in-human, Phase 1/2, open-label, dose escalation and expansion study, designed to evaluate the molecule’s safety, tolerability, and preliminary efficacy in patients with locally advanced or metastatic solid tumors, including HGSOC and sqNSCLC (NCT06799065).

Details for the presentation are as follows:

Poster Title: Robust anti-tumor activity of the novel KIF18A inhibitor, ATX-295, in preclinical models of chromosomally instable tumors
Abstract Number: 6641
Session Title: Multi-Axis Antineoplastic Agents
Session Date and Time: Tuesday, April 21: 2:00 PM – 5:00 PM PT
Location: Poster Section 14
Poster Board Number: 2
Presenter: Laura Ghisolfi, Ph.D.
About ATX-295
Accent’s lead program, ATX-295, is a potential best-in-class inhibitor for KIF18A, a mitotic kinesin motor protein critical for cell division in select tumors with chromosomal instability. KIF18A inhibitor treatment results in rapid cell death for cancers with an abnormal number of chromosomes (aneuploid) in vitro and in vivo, while cells with normal numbers of chromosomes (euploid) are unaffected. ATX-295 may address a large patient population across several cancer indications, including ovarian and squamous non-small cell lung cancer. Accent retains full worldwide rights to the KIF18A program, currently being evaluated in an ongoing Phase 1/2 clinical study (NCT06799065) enrolling patients with locally advanced or metastatic solid tumors, including high-grade serous ovarian cancer and squamous non-small cell lung cancer.

(Press release, Accent Therapeutics, APR 17, 2026, View Source [SID1234664483])

On April 17, 2026 OncoNano Medicine, Inc. ("OncoNano"), a clinical-stage biotechnology company developing precision therapies using its proprietary nanotechnology platform, reported it will present new preclinical data at the AACR (Free AACR Whitepaper) Annual Meeting 2026. The presentations highlight the breadth of its ON-BOARD platform and its ability to enable effective, tumor-targeted delivery of therapeutic payloads through clinically validated ultra pH-sensitive micelle technology designed to activate within the tumor microenvironment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our ON-BOARD platform is designed to overcome key limitations of existing delivery approaches, including reliance on tumor-associated antigens and off-tumor toxicities," said Kartik Krishnan, MD, PhD, Chief Executive Officer of OncoNano. "These data demonstrate the versatility of our platform across multiple payloads and reinforce its potential to deliver profound efficacy with an improved therapeutic index."

Poster Presentation Details

A Polymer-Drug Conjugate Platform for Tumor Specific Drug Delivery: Advancement of a Clinically Validated Ultra pH-Sensitive Micelle Technology
Presenter: Qingtai Su, PhD, Senior Scientist
Session Date/Time: April 20, 2026 | 2:00–5:00 PM PT
Location: Poster Section 14 | Board #17 | Poster #3026

This presentation highlights the breadth and tunability of the ON-BOARD platform, demonstrating tumor-specific delivery of multiple cytotoxic compounds through targeting the acidic tumor microenvironment. Preclinical data show strong in vitro and in vivo anti-tumor activity across a range of payload-linker combinations, including superior tumor growth inhibition and robust responses compared to standard-of-care agents. Findings further illustrate the ability to modulate payload release through linker design, supporting a differentiated, antigen-independent approach to drug delivery.

ONM-421, a pH-Responsive Polymer-Drug Conjugate Nanoparticle, Delivers MMAE to Solid Tumors and Shows Antigen-Independent Antitumor Efficacy in Mice
Presenter: Jason Miller, PhD, Associate Director
Session Date/Time: April 20, 2026 | 2:00–5:00 PM PT
Location: Poster Section 14 | Board #12 | Poster #3021

Building on the platform’s versatility, this presentation features ONM-421 as a lead example of ON-BOARD–enabled delivery. Preclinical findings demonstrate potent, antigen-independent anti-tumor efficacy across multiple xenograft models, including strong tumor growth inhibition and survival benefit. ONM-421 showed broader activity compared to an MMAE-based antibody-drug conjugate, including efficacy in tumors with low target expression where the ADC was less active. In these models, ONM-421 also demonstrated improved tolerability relative to a standard chemotherapy when given at an efficacious dose. These data highlight enhanced payload stability and protection during circulation, reinforcing the platform’s ability to enable targeted tumor delivery while reducing off-target toxicity.

(Press release, OncoNano Medicine, APR 17, 2026, View Source [SID1234664499])

On April 17, 2026 Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, reported preclinical data that showed powerful synergies between its two lead assets and emerging and foundational standard-of-care anti-cancer agents. Both ACR-368, a CHK1/2 inhibitor currently in a registrational-intent Phase 2b study, and ACR-2316, a WEE1/PKMYT1 inhibitor currently in a Phase 1/2 study, showed strong synergy in combination with anti-PD-L1 checkpoint inhibition. Additionally, ACR-368 synergized with a Topo 1 inhibitor, a payload commonly used in ADCs. The data will be presented at the AACR (Free AACR Whitepaper) 2026 Annual Meeting being held in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to be presenting these highly actionable data, mechanistically derived from our AP3 platform, at AACR (Free AACR Whitepaper)," said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and co-founder of Acrivon. "Our findings highlight attractive opportunities for future frontline development of ACR-368 and ACR-2316 in combination with immune checkpoint inhibitors and ADCs."

The posters can be found on the Acrivon website under "Posters and Presentations" or by using this LINK.

Poster Presentation Details:

Title Potent synergy between CHK1/2 inhibitor ACR-368 and the ADC payload topoisomerase 1 inhibitor: Rationale for ADC + ACR-368 combination therapy
Date and Time Sunday, April 19, 2026; 2:00 p.m. – 5:00 p.m. PT
Session Experimental and Molecular Therapeutics: DNA Damage and Repair 1
Poster Number 239

Title ACR-368 synergizes with PD-L1 blockade by coordinated activation of adaptive and innate immunity pathways to achieve robust anti-tumor efficacy
Date and Time Monday, April 20, 2026; 9:00 a.m. – 12:00 p.m. PT
Session Late-Breaking Research: Immunology 2
Poster Number LB152

Title Treatment with ACR-2316, a potential first- and best-in-class WEE1/PKMYT1 inhibitor, combined with anti-PD-L1 induces complete tumor regression with durable immune memory
Date and Time Monday, April 20, 2026; 2:00 p.m. – 5:00 p.m. PT
Session Clinical Research: Combination Immunotherapies
Poster Number 3789

(Press release, Acrivon Therapeutics, APR 17, 2026, View Source [SID1234664515])